Bipolar Depression


Once-daily valbenazine was effective and generally well tolerated in adults with tardive dyskinesia who took the drug for up to 48 weeks, according to a study published online in The Journal of Clinical Psychiatry.


Patients with bipolar disorder who have a high number of genes linked to schizophrenia are less likely to improve with lithium treatment, according to a newly published study.

The U.S. Food and Drug Administration has approved Otsuka Pharmaceutical Co Ltd's Abilify MyCite, the first drug with a digital ingestion tracking system to be approved in the United States.

Long-term use of benzodiazepine and nonbenzodiazepine hypnotics grew significantly in the United States between 1999 and 2014 apart from demographic shifts, according to a study published online in Psychiatric Services.

Presynaptic dopamine dysfunction is associated with psychosis across diagnostic categories and is a potential drug target for both bipolar disorder and schizophrenia, researchers say.



Rik de Greef, MSC, Thomas Kerbusch, PhD, Joannellyn Chiu, PhD, Timothy Carrothers, ScD
Sarah Ramsberger, Physician Assistant Student, Horacio Capote, MD, Director of Psychiatry, Michael Asbach, PA-C, Psych-CAQ
Joyce Tsai, PhD, Mauricio Tohen, MD, DrPH, MBA, Hans Kroger, MPH, MS, Andrei Pikalov, MD, PhD
Andrei Pikalov, MD, PhD, Joyce Tsai, PhD, Yongcai Mao, PhD, Robert Silva, PhD
Martha Sajatovic, MD, Brent Forester, MD, MSc, Joyce Tsai, PhD, Hans Kroger, MPH, MS